Journal
JOURNAL OF IMMUNOLOGY
Volume 187, Issue 1, Pages 181-189Publisher
AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.1003244
Keywords
-
Categories
Funding
- Grants-in-Aid for Scientific Research [23790067, 23590065, 21590675, 23390015] Funding Source: KAKEN
Ask authors/readers for more resources
Tyrosine kinase-2 (Tyk2), a member of the Jak family of kinases, mediates the signals triggered by various cytokines, including type I IFNs, IL-12, and IL-23. In the current study, we investigated the in vivo involvement of Tyk2 in several IL-12/Th1- and IL-23/Th17-mediated models of experimental diseases, including methylated BSA injection-induced footpad thickness, imiquimod-induced psoriasis-like skin inflammation, and dextran sulfate sodium-or 2,4,6-trinitrobenzene sulfonic acid-induced colitis. In these disease models, Tyk2 deficiency influenced the phenotypes in immunity and/or inflammation. Our findings demonstrate a somewhat broader contribution of Tyk2 to immune systems than previously expected and suggest that Tyk2 may represent an important candidate for drug development by targeting both the IL-12/Th1 and IL-23/Th17 axes. The Journal of Immunology, 2011, 187: 181-189.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available